ESMO 2023 Insights: "SWOG S1801 - Pathologic Response & Exploratory Analyses of Neoadjuvant-Adjuvant vs. Adjuvant Pembro for Resectable Stage 3B/4 Melanoma"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Find latest Skin videos · 400+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ESMO 2023 Insights: "SWOG S1801 - Pathologic Response & Exploratory Analyses of Neoadjuvant-Adjuvant vs. Adjuvant Pembro for Resectable Stage 3B/4 Melanoma"

By Insights from 2023 ESMO Annual Meeting FEATURING Sapna Patel

184 views

November 13, 2023

Comments 0

Melanoma in Children

Riccardo Pampena

911 views

Year in Review 2024 - Melanoma

Oncology 2024 Year in Review

A. van Akkooi

531 views

Year in Review 2024 - Key Updates in Melanoma Treatment

Oncology 2024 Year in Review

T. Haykal

285 views

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

540 views

Biomarkers for Immunotherapy in Melanoma: Where Are We Now?

Vanderbilt University Medical Center (VUMC)

D. Johnson

394 views

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

2.2K views

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

868 views

The Latest and Greatest in Melanoma Treatment, 2024: From Adjuvant t…

Melanoma Research Foundation

K. Margolin

173 views

Understanding TIL Cell Therapy and the Patient Journey for Advanced …

Melanoma Research Foundation

J. Lutzky

139 views

ESMO 2024 Summary: Metastatic Melanoma Highlights

2024 ESMO Annual Meeting Insights Hub

C. Blank

264 views

Medical Treatments for Melanoma: Current and Future Options

Melanoma Research Foundation

F. Collichio

208 views

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

327 views

Anti-IL-8 (BMS-986253) + Nivo + Ipi in Advanced Melanoma: Final Anal…

Matteo Simonelli

103 views

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters

215 views

New

Role of Nivolumab/Relatlimab in the 1L Treatment Landscape for Metas…

Rodabe Amaria

79 views

New

Optimal Therapy Sequence for 1L Treatment of BRAF-Mutated Metastatic…

Stanford Medicine

A. Betof Warner

69 views

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

802 views

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

612 views

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

2024 ESMO Annual Meeting Insights Hub

D. Johnson

231 views

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

833 views

AUTOPLAY

Login

Login

Join VuMedi

ESMO 2023 Insights: "SWOG S1801 - Pathologic Response & Exploratory Analyses of Neoadjuvant-Adjuvant vs. Adjuvant Pembro for Resectable Stage 3B/4 Melanoma"

Related Videos

Melanoma in Children

Year in Review 2024 - Melanoma

Year in Review 2024 - Key Updates in Melanoma Treatment

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Biomarkers for Immunotherapy in Melanoma: Where Are We Now?

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

The Latest and Greatest in Melanoma Treatment, 2024: From Adjuvant t…

Understanding TIL Cell Therapy and the Patient Journey for Advanced …

ESMO 2024 Summary: Metastatic Melanoma Highlights

Medical Treatments for Melanoma: Current and Future Options

ESMO 2024 Summary: Developmental Therapeutics Highlights

Anti-IL-8 (BMS-986253) + Nivo + Ipi in Advanced Melanoma: Final Anal…

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Role of Nivolumab/Relatlimab in the 1L Treatment Landscape for Metas…

Optimal Therapy Sequence for 1L Treatment of BRAF-Mutated Metastatic…

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

Advances in the Treatment of Melanoma